DK0972032T3 - Peptider til behandling af systemisk lupus erythematosus - Google Patents

Peptider til behandling af systemisk lupus erythematosus

Info

Publication number
DK0972032T3
DK0972032T3 DK98907114T DK98907114T DK0972032T3 DK 0972032 T3 DK0972032 T3 DK 0972032T3 DK 98907114 T DK98907114 T DK 98907114T DK 98907114 T DK98907114 T DK 98907114T DK 0972032 T3 DK0972032 T3 DK 0972032T3
Authority
DK
Denmark
Prior art keywords
lupus erythematosus
systemic lupus
peptides
treatment
laminin
Prior art date
Application number
DK98907114T
Other languages
English (en)
Inventor
Yaakov Naparstek
Original Assignee
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service filed Critical Hadasit Med Res Service
Application granted granted Critical
Publication of DK0972032T3 publication Critical patent/DK0972032T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK98907114T 1997-03-20 1998-03-20 Peptider til behandling af systemisk lupus erythematosus DK0972032T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12050397A IL120503A0 (en) 1997-03-20 1997-03-20 Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
PCT/IB1998/000415 WO1998042737A2 (en) 1997-03-20 1998-03-20 Peptides for the treatment of systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
DK0972032T3 true DK0972032T3 (da) 2007-04-10

Family

ID=11069947

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98907114T DK0972032T3 (da) 1997-03-20 1998-03-20 Peptider til behandling af systemisk lupus erythematosus

Country Status (13)

Country Link
US (1) US6228363B1 (da)
EP (1) EP0972032B1 (da)
JP (1) JP4459307B2 (da)
AT (1) ATE348885T1 (da)
AU (1) AU734444B2 (da)
CA (1) CA2283792A1 (da)
DE (1) DE69836679T2 (da)
DK (1) DK0972032T3 (da)
ES (1) ES2279567T3 (da)
IL (2) IL120503A0 (da)
NZ (1) NZ337953A (da)
PT (1) PT972032E (da)
WO (1) WO1998042737A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129052B1 (en) 2000-07-12 2006-10-31 The United States Of America As Represented By The Department Of Health And Human Services Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins
WO2001005812A2 (en) * 1999-07-15 2001-01-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services PEPTIDES AND THEIR UTILITY IN MODULATION OF BEHAVIOR OF CELLS EXPRESSING α3β1 INTEGRINS
US20020031788A1 (en) * 2000-02-18 2002-03-14 Rosenberg E. William Characterization of microbial deposition and immune response at the basement membrane and methods relating thereto
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
EA008438B1 (ru) * 2003-01-14 2007-06-29 Тева Фармасьютикал Индастриз, Лтд. Парентеральные композиции пептида для лечения системной красной волчанки
EA009123B1 (ru) * 2003-01-14 2007-10-26 Тева Фармасьютикал Индастриз, Лтд. Парентеральные композиции пептидов для лечения системной красной волчанки
CA2605321A1 (en) 2005-04-19 2006-10-26 Eli Lilly And Company Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
US20100285146A1 (en) * 2007-05-24 2010-11-11 Yaakov Naparstek Peptides and methods for the treatment of systemic lupus erythematosus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266328A (en) * 1990-08-27 1993-11-30 Regents Of The University Of Minnesota Laminin a chain polypeptides from the carboxy terminal globular domain
JPH06504271A (ja) 1990-09-14 1994-05-19 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 免疫グロブリンの構造に基づく生物活性なペプチドのデザイン
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
IL108811A (en) * 1994-03-01 1998-06-15 Hadasit Med Res Service Immunoassay reagents, kits and methods
US5493008A (en) * 1994-08-15 1996-02-20 The University Of Virginia Patent Foundation Two non-contiguous regions contribute to nidogen binding to a single EGF-like motif of the laminin γ1 chain
EP0765660A3 (en) * 1995-09-28 1998-09-23 Takeda Chemical Industries, Ltd. Microcapsules comprising 2-piperazinone-1-acetic acid compounds

Also Published As

Publication number Publication date
WO1998042737A3 (en) 1998-11-05
CA2283792A1 (en) 1998-10-01
DE69836679T2 (de) 2007-10-04
AU734444B2 (en) 2001-06-14
IL120503A0 (en) 1997-07-13
JP2001524826A (ja) 2001-12-04
NZ337953A (en) 2002-03-28
PT972032E (pt) 2007-03-30
ATE348885T1 (de) 2007-01-15
JP4459307B2 (ja) 2010-04-28
AU6306598A (en) 1998-10-20
DE69836679D1 (de) 2007-02-01
IL131950A (en) 2006-07-05
US6228363B1 (en) 2001-05-08
EP0972032A2 (en) 2000-01-19
WO1998042737A2 (en) 1998-10-01
ES2279567T3 (es) 2007-08-16
EP0972032B1 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
DE69533855D1 (de) UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG
DE59705683D1 (de) IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG
HUP0300246A2 (en) Delivery system
ES2133813T3 (es) Cadenas de lamininas: diagnostico y uso terapeutico.
ATE308327T1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
ATE242005T1 (de) P277 peptidanaloge, pharmazeutische zusammenstellung davon zur behandlung und diagnose von diabetes
DK0972032T3 (da) Peptider til behandling af systemisk lupus erythematosus
DE69329656T2 (de) Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen
GB2380939B (en) Treatment or prevention of auto-immune diseases
DE69625682T2 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
FI971427A (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
ATE178074T1 (de) Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
WO2008142694A3 (en) Peptides and methods for the treatment of systemic lupus erythematosus
DE69738600D1 (de) Neuroaktive peptide
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
NO963347D0 (no) Fremgangsmåte for identifisering av individer som lider av en cellulær abnormitet
DE69712182D1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
DE69326145T2 (de) Synthetische peptide für die behandlung von myasthenia gravis
FI973762A0 (fi) Ny gen
ATE260111T1 (de) Mittel zur behandlung von autoimmunkrankheiten
AU2791295A (en) Method of determining the amount of active substance released from solid or semi-solid preparations administered to humans or animals
IL114460A0 (en) Peptide p277 analogs and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes